Teva, one of the biggest generic makers, joins the the brand-name club
Teva launches Copaxone with the YpsoMate autoinjector from Ypsomed - Ypsomed - Canada
U.S. Court backs Teva multiple sclerosis drug patents | NASDAQ:TEVA
Teva Posts 2021 Earnings and Puts Opioid Litigation in Rearview Mirror | BioSpace
Teva defends Copaxone from Dutch patent challenge - PMLiVE
Teva finally dumps laquinimod, ending failure-riddled saga | Fierce Biotech
Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | BioSpace
New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis | Business Wire
Teva Long-Term Prospects Bright, Despite Headwinds - TipRanks.com
Biogen, Teva benefit as payers ease up on multiple sclerosis meddling: analyst | Fierce Pharma
Teva shares rally as FDA approves troubled drugmaker's migraine treatment | The Times of Israel
Teva loses Copaxone patent dispute case to Mylan in UK - Pharmaceutical Business review
Teva offers generic Tecfidera | Drug Store News
Active Biotech and Teva remain committed to clinical development program for multiple sclerosis
Feds accuse Teva of $300M in kickbacks for MS drug - Drug Discovery and Development
3rd Oral Drug to Treat MS Is Approved by the F.D.A. - The New York Times
High-Court-Sides-Teva-Patent
Teva reports new Copaxone data in breastfeeding mothers with relapsing multiple sclerosis | Seeking Alpha
Teva, Takeda To Commercialize Multiple Sclerosis Drug - Asian Scientist Magazine
Teva Pharmaceutical Industries Ltd. - Relapsing remitting #MS (RRMS) is the most common form of multiple sclerosis. Learn more about MS in our full infographic https://bit.ly/3fP8jvu #MultipleSclerosis #MSConnections #MS #WorldMSDay | Facebook
Virtual MS Medical Forum | Neurologybytes Events
Teva: It's Never Too Late to Sell | Barron's
NICE reconsiders and agrees to back Roche's Ocrevus in relapsing multiple sclerosis—with strings attached | Fierce Pharma
Teva Pharma Plunges After Two U.S. Copaxone Patents Invalidated | Investor's Business Daily
EU launches antitrust probe against Teva - www.israelhayom.com
